NEW YORK British drug developer Shire PLC is temporarily withdrawing from the market its product that treats attention deficit hyperactivity disorder, Forbes.com reported yesterday.
Shire decided to extract the Daytrana product line from the market after patients and caregivers complained that the patch’s release liner is difficult to detach, a problem for those who are trying to administer the drug. To mitigate the state of affairs, Shire stated they would provide easier-to-use patches to those affected by the market withdrawal.
Meanwhile, American depository shares of Shire fell 42 cents to $78.32 in pre-market trading yesterday. In a separate statement, Noven Pharmaceuticals, creator of Daytrana and other medications, estimated the damages at $4 million to $6 million.